Last reviewed · How we verify
Placebo booster
Placebo booster is a Biologic drug developed by Arcturus Therapeutics, Inc.. It is currently in Phase 3 development.
A placebo booster is a formulation designed to enhance the placebo effect through optimized delivery or presentation characteristics.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo booster |
|---|---|
| Sponsor | Arcturus Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
This appears to be an investigational approach by Arcturus Therapeutics to augment placebo response, potentially through improved formulation, delivery mechanism, or patient engagement strategies. The exact molecular or mechanistic basis is unclear from available public information. Placebo boosters are typically studied to understand contextual healing factors and optimize therapeutic outcomes in clinical settings.
Approved indications
Common side effects
Key clinical trials
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (PHASE1, PHASE2)
- UB-312 in Patients With Synucleinopathies (PHASE1)
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. (PHASE2)
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate (PHASE1, PHASE2)
- Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia (NA)
- Anthrax AV7909 Boost Evaluation Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo booster CI brief — competitive landscape report
- Placebo booster updates RSS · CI watch RSS
- Arcturus Therapeutics, Inc. portfolio CI
Frequently asked questions about Placebo booster
What is Placebo booster?
How does Placebo booster work?
Who makes Placebo booster?
What development phase is Placebo booster in?
Related
- Manufacturer: Arcturus Therapeutics, Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing